Literature DB >> 19037199

High levels of P-glycoprotein activity in human lymphocytes in the first 6 months of life.

C Giraud1, X Declèves, J Y Perrot, S Manceau, E Pannier, G Firtion, J P Morini, H Chappuy, F Batteux, S Chouzenoux, J M Scherrmann, S Blanche, J M Tréluyer.   

Abstract

P-glycoprotein (P-gp) is an efflux transporter that controls the intracellular concentrations of drugs. Human development may modulate P-gp function. We investigated the effect of age on P-gp activity and MDR1 gene expression in lymphocytes. We also assessed the influence of human immunodeficiency virus (HIV) infection. We used 3,3'-diethyloxacarbocyanin iodide (DiOC(6)) efflux, estimated by flow cytometry, to quantify P-gp activity in 94 children (age range, 0-18 years) and 25 adults. MDR1 gene expression was quantified using reverse transcription-PCR (RT-PCR). In T and natural killer (NK) cell populations, P-gp activity peaked at birth, decreased between the ages of 0 and 6 months, and stabilized between the ages of 6 months and 2 years (P < 10(-6)). These maturation profiles were also strongly correlated (r = 0.67, P < 10(-6)). HIV infection did not affect P-gp activity in the lymphocytes of children. MDR1 gene expression was not influenced by age, nor was it correlated with P-gp activity. The high levels of P-gp activity observed in the lymphocytes of children ~6 months of age may affect the efficacy of intracellular drugs.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 19037199     DOI: 10.1038/clpt.2008.221

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  4 in total

1.  Mind the Gaps: Ontogeny of Human Brain P-gp and Its Impact on Drug Toxicity.

Authors:  Jean-Marie Nicolas; Elizabeth C M de Lange
Journal:  AAPS J       Date:  2019-05-28       Impact factor: 4.009

2.  Placental transfer of maraviroc in an ex vivo human cotyledon perfusion model and influence of ABC transporter expression.

Authors:  C Vinot; L Gavard; J M Tréluyer; S Manceau; E Courbon; J M Scherrmann; X Declèves; D Duro; G Peytavin; L Mandelbrot; C Giraud
Journal:  Antimicrob Agents Chemother       Date:  2013-01-07       Impact factor: 5.191

3.  Plasma and intracellular tenofovir pharmacokinetics in the neonate (ANRS 12109 trial, step 2).

Authors:  Déborah Hirt; Didier K Ekouévi; Alain Pruvost; Saïk Urien; Elise Arrivé; Stéphane Blanche; Divine Avit; Clarisse Amani-Bosse; Mandisa Nyati; Shini Legote; Meng L Ek; Leakhena Say; James McIntyre; François Dabis; Jean-Marc Tréluyer
Journal:  Antimicrob Agents Chemother       Date:  2011-04-04       Impact factor: 5.191

4.  Developmental pharmacogenetics of CYP2C19 in neonates and young infants: omeprazole as a probe drug.

Authors:  Wei Zhao; Stéphanie Leroux; Valérie Biran; Evelyne Jacqz-Aigrain
Journal:  Br J Clin Pharmacol       Date:  2018-03-09       Impact factor: 4.335

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.